Clinical Trial Update: Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases [Phase 2]

View source ↗

Summary

A Phase II study is evaluating the combination of pembrolizumab and lenvatinib in patients with triple-negative breast cancer, non-small cell lung cancer, other…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain Metastases, Tumor | Phase 2 | Status: RECRUITING